Figure 3. cM7 synergizes with anti-CD40 to inhibit recipient CD8⁺ T cell infiltration into allografts.

WT B6 recipients received BALB/c skin grafts plus 10⁶ DST, and either no further treatment or anti-CD40 plus either the CD154/CD11b antagonist peptide cM7, or scM7 control peptide as described in Methods. Animals were sacrificed on day 10 and draining lymph nodes and skin grafts were analyzed. A, Representative flow cytometry plots summary data of absolute numbers of IFN-γ-producing CD8⁺ cells following ex vivo re-stimulation. B-D. Representative flow cytometry plots and summary data of absolute numbers of skin graft-infiltrating H-2K^b+ CD3⁺ CD8⁺ T cells (B), H-2K^b+ CD11b⁺cells (C) and H-2K^b+ F4/80⁺ cells (D). Data are representative of 3 independent experiments with a total 10–15 mice/group. *p<0.05 by one-way ANOVA with Kruskal-Wallis post-test. ns, not significant.